Medicus Pharma Announces $22 Million Non-Dilutive Financing

Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome

Medicus Pharma advances SkinJect program with FDA submission targeting Gorlin Syndrome

Medicus Pharma advances SkinJect toward registrational trial for rare Gorlin Syndrome

Medicus Pharma advances SkinJect for Gorlin syndrome – ICYMI

Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission

Medicus Pharma submits EU clinical trial modification for prostate cancer drug Teverelix

Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program

Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome

Medicus Pharma seeks rare pediatric disease tag for SkinJect in Gorlin Syndrome